Picture of Advanced Oncotherapy logo

AVO Advanced Oncotherapy News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

REG - AIM - AIM Notice - 10/05/2022

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220510:nRSJ8330Ka&default-theme=true

RNS Number : 8330K  AIM  10 May 2022

NOTICE

 

10/05/2022 - 08:00

 

The London Stock Exchange admits the following securities to trading on AIM:

 

 ADVANCED ONCOTHERAPY PLC
 3,540,000  ORDINARY SHARES OF 25P EACH, FULLY PAID  (BD6SX10)(GB00BD6SX109)

 

 BLOCK ENERGY PLC
 306,619  ORDINARY SHARES OF GBP0.0025 EACH FULLY PAID  (BF3TBT4)(GB00BF3TBT48)
 329,458  ORDINARY SHARES OF GBP0.0025 EACH FULLY PAID  (BF3TBT4)(GB00BF3TBT48)

 

 EGDON RESOURCES PLC
 400,000  ORDINARY SHARES OF 1P EACH, FULLY PAID  (B28YML2)(GB00B28YML29)

 

 FRANCHISE BRANDS PLC
 41,782  ORDINARY SHARES OF 0.5P EACH, FULLY PAID  (BD6P7Y2)(GB00BD6P7Y24)

 

 GEMFIELDS GROUP LIMITED
 2,942,757  ORDINARY SHARES OF USD0.00001 EACH, FULLY PAID  (BKFW1G3)(GG00BG0KTL52)

 

 KODAL MINERALS PLC
 1,071,428,569  ORDINARY SHARES OF 0.03125P EACH, FULLY PAID  (BH3X7Y7)(GB00BH3X7Y70)

 

 KORE POTASH PLC
 550,000  ORDINARY SHARES OF USD0.001 EACH, FULLY PAID  (BYP2QJ9)(GB00BYP2QJ94)

 

 PROSPEX ENERGY PLC
 1,000,000  ORDINARY SHARES OF 0.1P EACH, FULLY PAID  (BMFZVZ5)(GB00BMFZVZ53)

 

 SCIROCCO ENERGY PLC
 17,459,747  ORDINARY SHARES OF 0.20P EACH, FULLY PAID  (BF1BK40)(GB00BF1BK408)

 

 SOUTHERN ENERGY CORP.                                       BLOCK ADMISSION
 15,624,232   COMMON SHARES OF NO PAR VALUE FULLY PAID (DI)  (BNYL355)(CA8428133059)

 

If you have any queries or require further information, please contact Market
Operations on 020 7797 4310.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AMOBUGDUIDGDGDC

Recent news on Advanced Oncotherapy

See all news